NEOG Stock Overview
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$24.61|
|52 Week High||US$47.80|
|52 Week Low||US$22.12|
|1 Month Change||-6.44%|
|3 Month Change||-21.22%|
|1 Year Change||-46.44%|
|3 Year Change||-20.75%|
|5 Year Change||-5.04%|
|Change since IPO||9,529.83%|
Recent News & Updates
|NEOG||US Medical Equipment||US Market|
Return vs Industry: NEOG underperformed the US Medical Equipment industry which returned -25.1% over the past year.
Return vs Market: NEOG underperformed the US Market which returned -20.5% over the past year.
|NEOG Average Weekly Movement||5.0%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: NEOG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NEOG's weekly volatility (5%) has been stable over the past year.
About the Company
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
Neogen Fundamentals Summary
|NEOG fundamental statistics|
Is NEOG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NEOG income statement (TTM)|
|Cost of Revenue||US$278.79m|
Last Reported Earnings
Feb 28, 2022
Next Earnings Date
|Earnings per share (EPS)||0.46|
|Net Profit Margin||9.54%|
How did NEOG perform over the long term?See historical performance and comparison
Is NEOG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NEOG?
Other financial metrics that can be useful for relative valuation.
|What is NEOG's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does NEOG's PE Ratio compare to its peers?
|NEOG PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: NEOG is good value based on its Price-To-Earnings Ratio (54x) compared to the peer average (90.1x).
Price to Earnings Ratio vs Industry
How does NEOG's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?
Price-To-Earnings vs Industry: NEOG is expensive based on its Price-To-Earnings Ratio (54x) compared to the US Medical Equipment industry average (34.4x)
Price to Earnings Ratio vs Fair Ratio
What is NEOG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||54x|
|Fair PE Ratio||25.8x|
Price-To-Earnings vs Fair Ratio: NEOG is expensive based on its Price-To-Earnings Ratio (54x) compared to the estimated Fair Price-To-Earnings Ratio (25.8x).
Share Price vs Fair Value
What is the Fair Price of NEOG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NEOG ($24.61) is trading above our estimate of fair value ($6.37)
Significantly Below Fair Value: NEOG is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: NEOG is poor value based on its PEG Ratio (4.2x)
Discover undervalued companies
How is Neogen forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEOG's forecast earnings growth (12.9% per year) is above the savings rate (1.9%).
Earnings vs Market: NEOG's earnings (12.9% per year) are forecast to grow slower than the US market (13.9% per year).
High Growth Earnings: NEOG's earnings are forecast to grow, but not significantly.
Revenue vs Market: NEOG's revenue (6.4% per year) is forecast to grow slower than the US market (8.3% per year).
High Growth Revenue: NEOG's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NEOG's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Neogen performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEOG has high quality earnings.
Growing Profit Margin: NEOG's current net profit margins (9.5%) are lower than last year (13.7%).
Past Earnings Growth Analysis
Earnings Trend: NEOG's earnings have grown by 3.2% per year over the past 5 years.
Accelerating Growth: NEOG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NEOG had negative earnings growth (-20.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (12.9%).
Return on Equity
High ROE: NEOG's Return on Equity (5.6%) is considered low.
Discover strong past performing companies
How is Neogen's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: NEOG's short term assets ($609.6M) exceed its short term liabilities ($65.7M).
Long Term Liabilities: NEOG's short term assets ($609.6M) exceed its long term liabilities ($40.0M).
Debt to Equity History and Analysis
Debt Level: NEOG is debt free.
Reducing Debt: NEOG has not had any debt for past 5 years.
Debt Coverage: NEOG has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NEOG has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Neogen current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEOG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEOG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEOG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEOG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NEOG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Adent (53 yo)
Mr. John Edward Adent has been Chief Executive Officer at Neogen Corporation since July 17, 2017 and has been its President since September 22, 2017. He has been Director of Neogen Corporation since Octobe...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD2.51M) is below average for companies of similar size in the US market ($USD6.92M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: NEOG's management team is considered experienced (2 years average tenure).
Experienced Board: NEOG's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neogen Corporation's employee growth, exchange listings and data sources
- Name: Neogen Corporation
- Ticker: NEOG
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$2.578b
- Shares outstanding: 107.80m
- Website: https://www.neogen.com
Number of Employees
- Neogen Corporation
- 620 Lesher Place
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.